Physician profile
Tamara A Osborn
NPI 1699271577
$5,229.60
in general payments reported to CMS, 2019-2025
12 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 79% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,141 · 2024: $1,652 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,617 · Travel and Lodging: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,617.32 |
| Travel and Lodging | $1,612.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,154.68 | 2023-2025 | |
| Mentor Worldwide LLC | $626.45 | 2023-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Integra Lifesciences Corporation | $514.65 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Stryker Corporation | $352.64 | 2024-2025 | Na, Colorado |
| Musculoskeletal Transplant Foundation INC. | $334.73 | 2025 | |
| Polynovo North America LLC | $311.76 | 2024-2025 | Novosorb Btm |
| Medical Device Business Services, INC. | $203.60 | 2024 | Vistaseal |
| Innovation Technologies INC | $180.36 | 2024 | Irrisept |
| Depuy Synthes Sales INC. | $168.21 | 2024 | Trumatch, Matrixcombo |
| Baxter Healthcare | $151.02 | 2025 | Tisseel |
| Acera Surgical, INC. | $116.70 | 2025 | Restrata Wound Matrix |
| Ethicon US, LLC | $114.80 | 2023 | Stratafix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.